Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 7, 2019

Primary Completion Date

March 24, 2020

Study Completion Date

March 24, 2020

Conditions

HealthyRenal Insufficiency

Interventions

BIOLOGICAL

MGTA-145

MGTA-145 will be given intravenously

Trial Locations (2)

Orlando Clinical Research Center (OCRC), Orlando

Alliance for Multispeciality Research (AMR) Formerly New Orleans Center for Clinical Research (NOCCR), Knoxville